IsoRay signs US deal with BrachySciences
This article was originally published in Clinica
Executive Summary
IsoRay has signed up BrachySciences, an Oxford, Connecticut-based subsidiary of medtech firm Biocompatibles, as the US distributor of its Proxcelan Cesium-131 brachytherapy seeds. The two firms have signed an exclusive deal, which IsoRay (Richland, Washington) believes will increase its presence in the US prostate cancer therapy market. BrachySciences will also distribute the product in Puerto Rico. Financial terms of the deal were not disclosed. According to IsoRay, studies have demonstrated that Cesium-131 is able to deliver the required dose to prostate cancer patients, whilst potentially reducing unnecessary dose to critical structures such as the urethra and rectum.